行情

CPRX

CPRX

触媒制药公司
NASDAQ

实时行情|Nasdaq Last Sale

3.580
+0.100
+2.87%
交易中 15:44 04/02 EDT
开盘
3.420
昨收
3.480
最高
3.740
最低
3.420
成交量
135.30万
成交额
--
52周最高
7.67
52周最低
2.232
市值
3.70亿
市盈率(TTM)
11.98
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CPRX价格均价为8.83,最高价位11.00,最低价为7.00。

EPS

CPRX 新闻

更多
  • Catalyst Pharmaceuticals, Inc. Has 'Anti-Virus' Protection
  • Seeking Alpha - Article · 03/23 12:51
  • 5 Absurdly Cheap Biotech Stocks That Could Make You Filthy Rich
  • MotleyFool.com · 03/22 13:40
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Edited Transcript of CPRX earnings conference call or presentation 17-Mar-20 12:30pm GMT
  • Thomson Reuters StreetEvents · 03/18 00:21

所属板块

生物技术和医学研究
+1.90%
制药与医学研究
+1.93%

热门股票

代码
价格
涨跌幅

CPRX 简况

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
展开

微牛提供Catalyst Pharmaceuticals Inc(NASDAQ-CPRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CPRX股票新闻,以帮助您做出投资决策。